Standard Biotools (LAB) closed at $0.62 on October 28, 2026, up 0.2% from the previous close, on volume of 736,120 shares (30-day average 879,495).
Data as of October 28, 2026.
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Globe Newswire (Mon, 5-Oct 4:05 PM ET)
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Globe Newswire (Wed, 30-Sep 4:42 PM ET)
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 11-Sep 1:06 PM ET)
PRNewswire (Thu, 10-Sep 3:03 PM ET)
Globe Newswire (Thu, 10-Sep 8:20 AM ET)
Globe Newswire (Tue, 8-Sep 12:02 PM ET)
PRNewswire (Tue, 8-Sep 11:03 AM ET)
Standard BioTools Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Standard BioTools Exceeds 2025 Revenue Guidance, Projects $550M Cash Infusion from SomaLogic Sale
Market Chameleon (Thu, 8-Jan 6:52 AM ET)
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Standard Biotools trades on the NASDAQ stock market under the symbol LAB.
As of October 29, 2026, LAB stock price was flat at $0.62 with 67,288 million shares trading.
LAB has a beta of 1.62, meaning it tends to be more sensitive to market movements. LAB has a correlation of 0.08 to the broad based SPY ETF.
LAB has a market cap of $244.72 million. This is considered a Small Cap stock.
Last quarter Standard Biotools reported $20 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-816,000 and missed earnings estimates by -$.04.
In the last 3 years, LAB traded as high as $3.04 and as low as $.59.
The top ETF exchange traded funds that LAB belongs to (by Net Assets): VTI, VXF, IBB, SCHA, VHT.
LAB has underperformed the market in the last year with a price return of -51.2% while the SPY ETF gained +13.1%. LAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.0% and -1.9%, respectively, while the SPY returned +4.1% and -0.1%, respectively.
LAB support price is $.59 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LAB shares will trade within this expected range on the day.